Allegations of fraud and false advertising by the Federal Trade Commission and New York Attorney General Eric Schneiderman against the makers of a dietary supplement that claimed to improve memory function were dismissed in federal court Thursday.

U.S. District Judge Louis Stanton of the Southern District of New York granted the motions to dismiss in Federal Trade Commission v. Quincy Bioscience Holding Co., 17-cv-00124, by Quincy Bioscience, the maker of Prevagen, and its co-founders, Mark Underwood and Michael Beaman.

Charges were filed against the defendants in early January. Federal and state regulators accused the Wisconsin-based company of violating FTC regulations over false proof and unsubstantiated efficacy claims, while the AG's office brought false advertising and fraudulent acts claims.